Arcus Biosciences (RCUS) Gains from Investment Securities (2017 - 2025)
Historic Gains from Investment Securities for Arcus Biosciences (RCUS) over the last 9 years, with Q3 2025 value amounting to -$6.0 million.
- Arcus Biosciences' Gains from Investment Securities fell 50000.0% to -$6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.0 million, marking a year-over-year increase of 2142.86%. This contributed to the annual value of -$22.0 million for FY2024, which is 25714.29% down from last year.
- Arcus Biosciences' Gains from Investment Securities amounted to -$6.0 million in Q3 2025, which was down 50000.0% from $1.0 million recorded in Q2 2025.
- Over the past 5 years, Arcus Biosciences' Gains from Investment Securities peaked at $11.0 million during Q3 2023, and registered a low of -$10.0 million during Q2 2022.
- Moreover, its 5-year median value for Gains from Investment Securities was -$343500.0 (2021), whereas its average is -$388888.9.
- Data for Arcus Biosciences' Gains from Investment Securities shows a peak YoY increase of 1121111.11% (in 2022) and a maximum YoY decrease of 235098.04% (in 2022) over the last 5 years.
- Over the past 5 years, Arcus Biosciences' Gains from Investment Securities (Quarter) stood at $3.8 million in 2021, then crashed by 126.67% to -$1.0 million in 2022, then skyrocketed by 300.0% to $2.0 million in 2023, then tumbled by 400.0% to -$6.0 million in 2024, then changed by 0.0% to -$6.0 million in 2025.
- Its last three reported values are -$6.0 million in Q3 2025, $1.0 million for Q2 2025, and -$6.0 million during Q4 2024.